New drug cocktail shows promise for rare sarcomas
NCT ID NCT03526679
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a combination of two drugs, lenvatinib and eribulin, in 30 people with advanced soft tissue sarcomas (liposarcoma or leiomyosarcoma) that could not be removed by surgery or had spread. The goal was to see if the combo could shrink tumors or slow their growth. The trial is now complete, and results will help decide if this approach deserves further study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lenvatinib and eribulin
What this could lead to
If it works, this combination could offer a new treatment option for people with advanced soft tissue sarcomas that are hard to treat.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The drugs can cause side effects like fatigue, nausea, and high blood pressure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEIOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Taiwan University Hospital
Taipei, 100, Taiwan
-
Taipei Veterans General Hospital
Taipei, Taiwan, Taiwan